Related Experiment Video
Updated: Aug 20, 2025
Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome
Published on: July 5, 2024
Mineralocorticoid receptor blockade attenuates hyperandrogenic metabolic dysregulation in letrozole-induced PCOS rat
Efosa G Uhunmwangho1, Adesola A Oniyide1, Stephanie E Areloegbe1
1Cardio/Repro-Metabolic and Microbiome Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, 360101 Nigeria.
Purpose:
Polycystic ovarian syndrome (PCOS) is a metabolic syndrome associated with mineralocorticoid receptor (MR) activation, which causes infertility in women of reproductive age. Spironolactone (SPL) is a MR blocker with inconclusive effect in the treatment of PCOS. Therefore, the present study hypothesized that low dose SPL would ameliorate metabolic dysfunction associated with PCOS.
Methods:
Female Wistar rats (8-week-old) were divided into 3 groups namely: Control, SPL, Letrozole (LET)-treated and LET + SPL-treated groups. The control group was given vehicle (distilled water), SPL-treated group received 0.25 mg/kg, LET-treated group received 1 mg/kg of LET and LET + SPL-treated group received a combination of LET and SPL. The administrations were done by oral gavage for 21 days uninterruptedly. Biochemical parameters such as lipid profile, malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), γ-glutamyl transferase (GGT), lactate dehydrogenase (LDH), testosterone, 17-β estradiol and glutathione peroxidase (GPx) were determined with appropriate assay methods.
Results:
Letrozole-treated group had a significant increase in ovarian weight, plasma and ovarian triglycerides, MDA/TNF-α, GGT/LDH and plasma testosterone while it decreased plasma 17-β estradiol and plasma/ovarian high-density lipoproteins and GPx when compared with control group. In addition, histomorphological changes were observed in LET-treated group compared with control group. Nevertheless, administration of low dose SPL attenuated these perturbations.
Conclusion:
The present study therefore demonstrates that inhibition of mineralocorticoid receptor by low dose SPL ameliorates hyperandrogenic metabolic dysfunction in a rat model of PCOS. Therefore, low dose SPL is hereby suggested as a promising therapeutic agent in the management of PCOS.
Insights
Low-dose spironolactone (SPL) effectively treats metabolic dysfunction in a rat model of polycystic ovarian syndrome (PCOS). This mineralocorticoid receptor blocker shows promise for managing PCOS symptoms and infertility.
Area of Science:
- Endocrinology
- Reproductive Biology
- Metabolic Syndrome
Background:
- Polycystic ovarian syndrome (PCOS) is a common endocrine disorder characterized by metabolic dysfunction and infertility.
- Mineralocorticoid receptor (MR) activation is implicated in PCOS pathophysiology.
- Spironolactone (SPL), an MR blocker, has shown inconsistent results in PCOS treatment.
Purpose of the Study:
- To investigate the efficacy of low-dose spironolactone (SPL) in ameliorating metabolic dysfunction associated with PCOS.
- To evaluate the impact of SPL on hormonal and biochemical markers in a PCOS rat model.
Main Methods:
- Female Wistar rats were administered letrozole (LET) to induce PCOS, with groups receiving vehicle, SPL, LET, or LET + SPL.
- Biochemical parameters including lipid profile, oxidative stress markers (MDA, TNF-α, GPx), liver enzymes (GGT, LDH), and reproductive hormones (testosterone, estradiol) were measured.
- Histomorphological changes in ovarian tissue were assessed.
Main Results:
- Letrozole-induced PCOS in rats led to increased ovarian weight, dyslipidemia, oxidative stress, elevated liver enzymes, and hyperandrogenism.
- Low-dose SPL administration significantly attenuated these PCOS-associated metabolic and hormonal disturbances.
- Histological analysis revealed amelioration of ovarian abnormalities following SPL treatment.
Conclusions:
- Low-dose spironolactone effectively ameliorates hyperandrogenic metabolic dysfunction in a PCOS rat model.
- Inhibition of the mineralocorticoid receptor by SPL offers a promising therapeutic strategy for PCOS management.
- Further clinical studies are warranted to confirm SPL's efficacy in treating PCOS in women.
